Loading...

You're on the old version of Simply Wall St. We will no longer be supporting this site, so we recommend you switch to our brand new platform.

Gerresheimer

BATS-CHIXE:GXID
Snowflake Description

Slightly overvalued with limited growth.

The Snowflake is generated from 30 checks in 5 different areas, read more below.
GXID
BATS-CHIXE
€2B
Market Cap
  1. Home
  2. GB
  3. Pharmaceuticals & Biotech
Company description

Gerresheimer AG manufactures and sells specialty glass and plastic products primarily for the pharma and healthcare industry worldwide. The last earnings update was 41 days ago. More info.


Add to Portfolio Compare Print
  • Gerresheimer has significant price volatility in the past 3 months.
GXID Share Price and Events
7 Day Returns
-0.7%
BATS-CHIXE:GXID
19.9%
GB Life Sciences
10%
GB Market
1 Year Returns
-18.2%
BATS-CHIXE:GXID
-15.8%
GB Life Sciences
-23%
GB Market
GXID Shareholder Return
  7 Day 30 Day 90 Day 1 Year 3 Year 5 Year
Gerresheimer (GXID) -0.7% -13.4% -19.1% -18.2% -24.3% 8.3%
GB Life Sciences 19.9% -20.4% -32% -15.8% -16.1% -24.9%
GB Market 10% -17.6% -27.3% -23% -24.2% -21.8%
1 Year Return vs Industry and Market
  • GXID underperformed the Life Sciences industry which returned -15.8% over the past year.
  • GXID outperformed the Market in United Kingdom of Great Britain and Northern Ireland which returned -23% over the past year.
Price Volatility
GXID
Industry
5yr Volatility vs Market

GXID Value

 Is Gerresheimer undervalued based on future cash flows and its price relative to the stock market?

Value is all about what a company is worth versus what price it is available for. If you went into a grocery store and all the bananas were on sale at half price, they could be considered undervalued.
INTRINSIC VALUE BASED ON FUTURE CASH FLOWS
Here we compare the current share price of Gerresheimer to its discounted cash flow analysis.value.

The discounted cash flow value is simply looking at what the company is worth today, based on estimates of how much money it is expected to make in the future.
Raw Data

Below are the data sources, inputs and calculation used to determine the intrinsic value for Gerresheimer.

BATS-CHIXE:GXID Discounted Cash Flow Data Sources
Data Point Source Value
Valuation Model 2 Stage Free Cash Flow to Equity
Levered Free Cash Flow Average of 12 Analyst Estimates (S&P Global) See below
Discount Rate (Cost of Equity) See below 7.6%
Perpetual Growth Rate 10-Year GB Government Bond Rate 0.5%

An important part of a discounted cash flow is the discount rate, below we explain how it has been calculated.

Calculation of Discount Rate/ Cost of Equity for BATS-CHIXE:GXID
Data Point Calculation/ Source Result
Risk-Free Rate 10-Year GB Govt Bond Rate 0.5%
Equity Risk Premium S&P Global 5.4%
Life Sciences Unlevered Beta Simply Wall St/ S&P Global 1.03
Re-levered Beta = Unlevered beta (1 + (1- tax rate) (Debt/Equity))
= 1.033 (1 + (1- 30%) (57.96%))
1.303
Levered Beta Levered Beta limited to 0.8 to 2.0
(practical range for a stable firm)
1.3
Discount Rate/ Cost of Equity = Cost of Equity = Risk Free Rate + (Levered Beta * Equity Risk Premium)
= 0.53% + (1.303 * 5.44%)
7.62%

Discounted Cash Flow Calculation for BATS-CHIXE:GXID using 2 Stage Free Cash Flow to Equity Model

The calculations below outline how an intrinsic value for Gerresheimer is arrived at by discounting future cash flows to their present value using the 2 stage method. We try to start with analysts estimates of free cash flow, however if these are not available we use the most recent financial results. In the 1st stage we continue to grow the free cash flow over a 10 year period, with the growth rate trending towards the perpetual growth rate used in the 2nd stage. The 2nd stage assumes the company grows at a stable rate into perpetuity.

Note: Free cash flow to equity valuations ignore the company's cash or debt.

BATS-CHIXE:GXID DCF 1st Stage: Next 10 year cash flow forecast
Levered FCF (EUR, Millions) Source Present Value
Discounted (@ 7.62%)
2020 63.92 Analyst x6 59.39
2021 133.33 Analyst x6 115.13
2022 146.40 Analyst x2 117.46
2023 158.50 Analyst x1 118.17
2024 170.50 Analyst x1 118.12
2025 178.76 Est @ 4.85% 115.08
2026 185.11 Est @ 3.55% 110.73
2027 190.01 Est @ 2.65% 105.61
2028 193.83 Est @ 2.01% 100.11
2029 196.87 Est @ 1.57% 94.48
Present value of next 10 years cash flows €1,054.00
BATS-CHIXE:GXID DCF 2nd Stage: Terminal Value
Calculation Result
Terminal Value = FCF2029 × (1 + g) ÷ (Discount Rate – g)
= €196.87 × (1 + 0.53%) ÷ (7.62% – 0.53%)
€2,792.45
Present Value of Terminal Value = Terminal Value ÷ (1 + r)10
= €2,792.45 ÷ (1 + 7.62%)10
€1,340.18
BATS-CHIXE:GXID Total Equity Value
Calculation Result
Total Equity Value = Present value of next 10 years cash flows + Terminal Value
= €1,054.00 + €1,340.18
€2,394.18
Equity Value per Share
(EUR)
= Total value / Shares Outstanding
= €2,394.18 / 31.40
€76.25
BATS-CHIXE:GXID Discount to Share Price
Calculation Result
Non-primary Listing Adjustment Factor 1 share in BATS-CHIXE:GXID represents 0.97145x of XTRA:GXI
(This could be a different class, a depositary receipt, a different currency, or all of these things.)
0.97145x
Value per Share
(Listing Adjusted, EUR)
= Value per Share (EUR) x Listing Adjustment Factor
= € 76.25 x 0.97145
€74.07
Value per share (EUR) From above. €74.07
Current discount Discount to share price of €56.15
= -1 x (€56.15 - €74.07) / €74.07
24.2%

Learn more about our DCF calculations in Simply Wall St’s analysis model .

Current Discount
Amount off the current price Gerresheimer is available for.
Intrinsic value
24%
Share price is €56.15 vs Future cash flow value of €74.07
Current Discount Checks
For Gerresheimer to be considered undervalued it must be available for at least 20% below the current price. Less than 40% is even better.
  • Gerresheimer's share price is below the future cash flow value, and at a moderate discount (> 20%).
  • Gerresheimer's share price is below the future cash flow value, but not at a substantial discount (< 40%).
PRICE RELATIVE TO MARKET
We can also value a company based on what the stock market is willing to pay for it. This is similar to the price of fruit (e.g. Mangoes or Avocados) increasing when they are out of season, or how much your home is worth.

The amount the stock market is willing to pay for Gerresheimer's earnings, growth and assets is considered below, and whether this is a fair price.
Price based on past earnings
Are Gerresheimer's earnings available for a low price, and how does this compare to other companies in the same industry?
Raw Data
BATS-CHIXE:GXID PE (Price to Earnings) Ratio Data Sources
Data Point Source Value
Earnings Per Share * Company Filings (2019-11-30) in EUR €2.57
XTRA:GXI Share Price ** XTRA (2020-03-30) in EUR €57.8
Europe Life Sciences Industry PE Ratio Median Figure of 18 Publicly-Listed Life Sciences Companies 48.4x
United Kingdom of Great Britain and Northern Ireland Market PE Ratio Median Figure of 747 Publicly-Listed Companies 12.45x

* Trailing twelve months (TTM) annual GAAP earnings per share excluding extraordinary items.

** Primary Listing of Gerresheimer.

BATS-CHIXE:GXID PE (Price to Earnings) Ratio Calculation
Calculation Outcome
PE Ratio

= XTRA:GXI Share Price ÷ EPS (both in EUR)

= 57.8 ÷ 2.57

22.47x

Learn more about our ratios and growth rates in Simply Wall St’s analysis model >

  • Gerresheimer is good value based on earnings compared to the Europe Life Sciences industry average.
  • Gerresheimer is overvalued based on earnings compared to the United Kingdom of Great Britain and Northern Ireland market.
Price based on expected Growth
Does Gerresheimer's expected growth come at a high price?
Raw Data
BATS-CHIXE:GXID PEG (Price to Earnings to Growth) Ratio Data Sources
Data Point Source Value
PE Ratio See PE Ratio Section 22.47x
Net Income Annual Growth Rate See Future Growth Section.
Line of Best Fit* through Consensus Estimate Earnings of 12 Analysts
13%per year
Europe Life Sciences Industry PEG Ratio Median Figure of 15 Publicly-Listed Life Sciences Companies 2.05x
United Kingdom of Great Britain and Northern Ireland Market PEG Ratio Median Figure of 526 Publicly-Listed Companies 0.95x

*Line of best fit is calculated by linear regression .

BATS-CHIXE:GXID PEG (Price to Earnings to Growth) Ratio Calculation
Calculation Outcome
PEG Ratio

= PE Ratio ÷ Net Income Annual Growth Rate

= 22.47x ÷ 13%

1.72x

Learn more about our ratios and growth rates in Simply Wall St’s analysis model >

  • Gerresheimer is poor value based on expected growth next year.
Price based on value of assets
What value do investors place on Gerresheimer's assets?
Raw Data
BATS-CHIXE:GXID PB (Price to Book) Ratio Data Sources
Data Point Source Value
Book Value per Share Company Filings (2019-11-30) in EUR €29.46
XTRA:GXI Share Price * XTRA (2020-03-30) in EUR €57.8
United Kingdom of Great Britain and Northern Ireland Life Sciences Industry PB Ratio Median Figure of 13 Publicly-Listed Life Sciences Companies 1.88x
United Kingdom of Great Britain and Northern Ireland Market PB Ratio Median Figure of 1,322 Publicly-Listed Companies 1.08x
BATS-CHIXE:GXID PB (Price to Book) Ratio Calculation
Calculation Outcome
PB Ratio

= XTRA:GXI Share Price ÷ Book Value per Share (both in EUR)

= 57.8 ÷ 29.46

1.96x

* Primary Listing of Gerresheimer.

Learn more about our ratios and growth rates in Simply Wall St’s analysis model >

  • Gerresheimer is overvalued based on assets compared to the GB Life Sciences industry average.
X
Value checks
We assess Gerresheimer's value by looking at:
  1. Is the discounted cash flow value less than 20%, or 40% of the share price? (2 checks) ( Click here or on bar chart for details of DCF calculation. )
  2. Is the PE ratio less than the market average, and/ or less than the Life Sciences industry average (and greater than 0)? (2 checks)
  3. Is the PEG ratio within a reasonable range (0 to 1)? (1 check)
  4. Is the PB ratio less than the Life Sciences industry average (and greater than 0)? (1 check)
  5. Gerresheimer has a total score of 2/6, see the detailed checks below.

    Note: We use GAAP Earnings per Share in all our calculations including PE and PEG Ratio.

    Full details on the Value part of the Simply Wall St company analysis model.

GXID Future Performance

 How is Gerresheimer expected to perform in the next 1 to 3 years based on estimates from 12 analysts?

The future performance of a company is measured in the same way as past performance, by looking at estimated growth and how much profit it is expected to make.

Future estimates come from professional analysts. Just like forecasting the weather, they don’t always get it right!
Annual Growth Rate
13%
Expected annual growth in earnings.
Earnings growth vs Low Risk Savings
Is Gerresheimer expected to grow at an attractive rate?
  • Gerresheimer's earnings growth is expected to exceed the low risk savings rate of 0.5%.
Growth vs Market Checks
  • Gerresheimer's earnings growth is positive but not above the United Kingdom of Great Britain and Northern Ireland market average.
  • Gerresheimer's revenue growth is expected to exceed the United Kingdom of Great Britain and Northern Ireland market average.
Annual Growth Rates Comparison
Raw Data
BATS-CHIXE:GXID Future Growth Rates Data Sources
Data Point Source Value (per year)
BATS-CHIXE:GXID Future Earnings Growth Rate Line of Best Fit* through Consensus Estimate Earnings of 12 Analysts 13%
BATS-CHIXE:GXID Future Revenue Growth Rate Line of Best Fit* through Consensus Estimate Revenue of 12 Analysts 5.4%
United Kingdom of Great Britain and Northern Ireland Life Sciences Industry Earnings Growth Rate Market Cap Weighted Average 43.5%
United Kingdom of Great Britain and Northern Ireland Life Sciences Industry Revenue Growth Rate Market Cap Weighted Average -10.3%
United Kingdom of Great Britain and Northern Ireland Market Earnings Growth Rate Market Cap Weighted Average 15.5%
United Kingdom of Great Britain and Northern Ireland Market Revenue Growth Rate Market Cap Weighted Average 2.3%

*Line of best fit is calculated by linear regression .

Industry and Market average data is calculated daily.

Learn more about our growth rate calculations in Simply Wall St’s analysis model.

Analysts growth expectations
Raw Data
BATS-CHIXE:GXID Analysts Growth Expectations Data Sources
Data Point Source Value
Past Financials Company Filings (4 months ago) See Below
Future Estimates Average of up to 12 Analyst Estimates (S&P Global) See Below
All numbers in EUR Millions and using Trailing twelve months (TTM) annual period rather than quarterly.
BATS-CHIXE:GXID Future Estimates Data
Date (Data in EUR Millions) Revenue Cash Flow Net Income * Avg. No. Analysts
2024-11-30 1,827 327 144 4
2023-11-30 1,733 305 138 5
2022-11-30 1,633 286 122 6
2021-11-30 1,548 267 101 12
2020-11-30 1,462 231 83 7
2020-03-31
BATS-CHIXE:GXID Past Financials Data
Date (Data in EUR Millions) Revenue Cash Flow Net Income *
2019-11-30 1,392 193 81
2019-08-31 1,415 161 207
2019-05-31 1,410 183 207
2019-02-28 1,386 159 179
2018-11-30 1,368 173 129
2018-08-31 1,351 184 124
2018-05-31 1,329 192 131
2018-02-28 1,336 206 137
2017-11-30 1,348 219 101
2017-08-31 1,331 184 49
2017-05-31 1,350 176 53
2017-02-28 1,358 190 56

*GAAP earnings excluding extraordinary items.

Super high growth metrics
High Growth Checks
  • Gerresheimer's earnings are expected to grow by 13% yearly, however this is not considered high growth (20% yearly).
  • Gerresheimer's revenue is expected to grow by 5.4% yearly, however this is not considered high growth (20% yearly).
Past and Future Earnings per Share
The accuracy of the analysts who estimate the future performance data can be gauged below. We look back 3 years and see if they were any good at predicting what actually occurred. We also show the highest and lowest estimates looking forward to see if there is a wide range.
Raw Data
BATS-CHIXE:GXID Past and Future Earnings per Share
Data Point Source Value
Past Financials Company Filings (4 months ago) See Below
Future Estimates Average of up to 12 Analyst Estimates (S&P Global) See Below

All data from Gerresheimer Company Filings, last reported 4 months ago, and in Trailing twelve months (TTM) annual period rather than quarterly.

BATS-CHIXE:GXID Future Estimates Data
Date (Data in EUR Millions) EPS * EPS High Estimate EPS Low Estimate Avg. No. Analysts
2024-11-30 4.57 4.57 4.57 1.00
2023-11-30 4.38 4.62 4.14 2.00
2022-11-30 3.89 4.44 3.47 5.00
2021-11-30 3.34 3.83 2.95 9.00
2020-11-30 2.63 2.81 2.43 7.00
2020-03-31
BATS-CHIXE:GXID Past Financials Data
Date (Data in EUR Millions) EPS *
2019-11-30 2.57
2019-08-31 6.59
2019-05-31 6.59
2019-02-28 5.71
2018-11-30 4.11
2018-08-31 3.94
2018-05-31 4.17
2018-02-28 4.35
2017-11-30 3.21
2017-08-31 1.55
2017-05-31 1.70
2017-02-28 1.78

*GAAP earnings excluding extraordinary items.

Performance in 3 years
In the same way as past performance we look at the future estimated return (profit) compared to the available funds. We do this looking forward 3 years.
  • Gerresheimer is not expected to efficiently use shareholders’ funds in the future (Return on Equity less than 20%).
X
Future performance checks
We assess Gerresheimer's future performance by looking at:
  1. Is the annual earnings growth rate expected to beat the low risk savings rate, plus a premium to keep pace with inflation?
  2. Is the annual earnings growth rate expected to beat the average growth rate in earnings of the United Kingdom of Great Britain and Northern Ireland market? (1 check)
  3. Is the annual revenue growth rate expected to beat the average growth rate in revenue of the United Kingdom of Great Britain and Northern Ireland market? (1 check)
  4. Is the annual earnings growth rate expected to be above 20%? (1 check)
  5. Is the annual revenue growth rate expected to be above 20%? (1 check)
  6. Is the Return on Equity in 3 years expected to be over 20%? (1 check)
Some of the above checks will fail if the company is expected to be loss making in the relevant year.
Gerresheimer has a total score of 2/6, see the detailed checks below.

Note 1: We use GAAP Net Income Excluding Exceptional Items for our Earnings in all our calculations.

Full details on the Future part of the Simply Wall St company analysis model.

GXID Past Performance

  How has Gerresheimer performed over the past 5 years?

The past performance of a company can be measured by how much growth it has experienced and how much profit it makes relative to the funds and assets it has available.
Past earnings growth
Below we compare Gerresheimer's growth in the last year to its industry (Life Sciences).
Past Earnings growth analysis
We also check if the company has grown in the past 5 years, and whether it has maintained that growth in the year.
  • Gerresheimer's year on year earnings growth rate has been positive over the past 5 years, however the most recent earnings are below average.
  • Gerresheimer's 1-year earnings growth is negative, it can't be compared to the 5-year average.
  • Gerresheimer's 1-year earnings growth is negative, it can't be compared to the Europe Life Sciences industry average.
Earnings and Revenue History
Gerresheimer's revenue and profit over the past 5 years is shown below, any years where they have experienced a loss will show up in red.
Raw Data

All data from Gerresheimer Company Filings, last reported 4 months ago, and in Trailing twelve months (TTM) annual period rather than quarterly.

BATS-CHIXE:GXID Past Revenue, Cash Flow and Net Income Data
Date (Data in EUR Millions) Revenue Net Income * G+A Expenses R&D Expenses
2019-11-30 1,392.26 80.78 273.17
2019-08-31 1,414.76 207.08 274.82
2019-05-31 1,409.77 207.04 271.62
2019-02-28 1,385.90 179.24 266.67
2018-11-30 1,367.73 128.97 259.41
2018-08-31 1,351.05 123.68 258.37
2018-05-31 1,328.92 130.86 256.35
2018-02-28 1,335.81 136.63 258.31
2017-11-30 1,348.26 100.89 258.61
2017-08-31 1,331.44 48.63 257.41
2017-05-31 1,350.33 53.27 259.28
2017-02-28 1,358.12 55.97 258.19
2016-11-30 1,375.46 57.92 258.68
2016-08-31 1,298.53 118.42 242.83
2016-05-31 1,292.18 106.39 239.78
2016-02-29 1,301.30 99.43 237.67
2015-11-30 1,282.91 95.57 231.33
2015-08-31 1,335.40 69.40 236.29
2015-05-31 1,315.31 69.39 235.38
2015-02-28 1,294.29 68.40 230.31
2014-11-30 1,290.02 66.34 227.90
2014-08-31 1,282.09 71.27 234.77
2014-05-31 1,275.08 71.07 230.79
2014-02-28 1,266.72 62.51 235.23
2013-11-30 1,265.93 62.16 237.22
2013-08-31 1,265.54 63.93 232.91
2013-05-31 1,260.08 59.44 235.13

*GAAP earnings excluding extraordinary items.

Performance last year
We want to ensure a company is making the most of what it has available. This is done by comparing the return (profit) to a company's available funds, assets and capital.
  • Gerresheimer has not efficiently used shareholders’ funds last year (Return on Equity less than 20%).
  • Gerresheimer used its assets less efficiently than the Europe Life Sciences industry average last year based on Return on Assets.
  • Gerresheimer's use of capital deteriorated last year versus 3 years ago (Return on Capital Employed).
X
Past performance checks
We assess Gerresheimer's performance over the past 5 years by checking for:
  1. Has earnings increased in past 5 years? (1 check)
  2. Has the earnings growth in the last year exceeded that of the Life Sciences industry? (1 check)
  3. Is the recent earnings growth over the last year higher than the average annual growth over the past 5 years? (1 check)
  4. Is the Return on Equity (ROE) higher than 20%? (1 check)
  5. Is the Return on Assets (ROA) above industry average? (1 check)
  6. Has the Return on Capital Employed (ROCE) increased from 3 years ago? (1 check)
The above checks will fail if the company has reported a loss in the most recent earnings report. Some checks require at least 3 or 5 years worth of data.
Gerresheimer has a total score of 1/6, see the detailed checks below.

Note: We use GAAP Net Income excluding extraordinary items in all our calculations.

Full details on the Past part of the Simply Wall St company analysis model.

GXID Health

 How is Gerresheimer's financial health and their level of debt?

A company's financial position is much like your own financial position, it includes everything you own (assets) and owe (liabilities).

The boxes below represent the relative size of what makes up Gerresheimer's finances.

The net worth of a company is the difference between its assets and liabilities.
Net Worth
  • Gerresheimer's short term (1 year) commitments are greater than its holdings of cash and other short term assets.
  • Gerresheimer's long term commitments exceed its cash and other short term assets.
Balance sheet
This treemap shows a more detailed breakdown of Gerresheimer's finances. If any of them are yellow this indicates they may be out of proportion and red means they relate to one of the checks below.
Assets
Liabilities and shares
The 'shares' portion represents any funds contributed by the owners (shareholders) and any profits.
  • High level of physical assets or inventory.
  • Debt is not covered by short term assets, assets are 0.5x debt.
Historical Debt
Nearly all companies have debt. Debt in itself isn’t bad, however if the debt is too high, or the company can’t afford to pay the interest on its debts this may have impacts in the future.

The graphic below shows equity (available funds) and debt, we ideally want to see the red area (debt) decreasing.

If there is any debt we look at the companies capability to repay it, and whether the level has increased over the past 5 years.
Raw Data

All data from Gerresheimer Company Filings, last reported 4 months ago.

BATS-CHIXE:GXID Past Debt and Equity Data
Date (Data in EUR Millions) Total Equity Total Debt Cash & Short Term Investments
2019-11-30 941.56 1,016.06 94.08
2019-08-31 1,028.98 679.05 96.80
2019-05-31 1,050.01 677.89 111.37
2019-02-28 993.77 677.68 101.37
2018-11-30 890.13 957.32 86.37
2018-08-31 824.60 1,188.96 111.36
2018-05-31 822.92 890.54 112.87
2018-02-28 823.92 1,028.53 293.27
2017-11-30 789.53 989.36 294.13
2017-08-31 750.67 908.12 130.77
2017-05-31 752.03 920.45 102.32
2017-02-28 789.89 940.34 131.48
2016-11-30 763.30 896.23 121.03
2016-08-31 725.06 1,016.04 133.79
2016-05-31 687.82 1,020.51 112.29
2016-02-29 688.03 1,006.76 95.84
2015-11-30 698.13 961.12 94.44
2015-08-31 612.80 530.05 74.49
2015-05-31 615.17 552.31 76.84
2015-02-28 623.51 534.09 72.18
2014-11-30 604.37 479.85 67.94
2014-08-31 584.79 536.95 63.44
2014-05-31 570.57 560.42 82.36
2014-02-28 570.94 519.75 65.29
2013-11-30 563.41 476.03 73.09
2013-08-31 530.96 526.35 70.11
2013-05-31 535.17 573.65 93.43
  • Gerresheimer's level of debt (107.9%) compared to net worth is high (greater than 40%).
  • The level of debt compared to net worth has increased over the past 5 years (79.5% vs 107.9% today).
  • Debt is not well covered by operating cash flow (19%, less than 20% of total debt).
  • Interest payments on debt are well covered by earnings (EBIT is 5.2x coverage).
X
Financial health checks
We assess Gerresheimer's financial health by checking for:
  1. Are short term assets greater than short term liabilities? (1 check)
  2. Are short term assets greater than long term liabilities? (1 check)
  3. Has the debt to equity ratio increased in the past 5 years? (1 check)
  4. Is the debt to equity ratio over 40%? (1 check)
  5. Is the debt covered by operating cash flow? (1 check)
  6. Are earnings greater than 5x the interest on debt (if company pays interest at all)? (1 check)
  7. Gerresheimer has a total score of 1/6, see the detailed checks below.
For companies that are loss making and have been so on average in the past we replace the last 2 checks with:
  1. Does cash and short term investments cover stable operating expenses (recurring G&A and R&D) for more than 3 years? (1 check)
  2. Does cash and short term investments cover growing operating expenses (recurring G&A and R&D) for more than 3 years? (1 check)


Full details on the Health part of the Simply Wall St company analysis model.

GXID Dividends

 What is Gerresheimer's current dividend yield, its reliability and sustainability?

Dividends are regular cash payments to you from the company, similar to a bank paying you interest on a savings account.
Annual Dividend Income
Dividend payments
2.08%
Current annual income from Gerresheimer dividends. Estimated to be 2.18% next year.
If you bought €2,000 of Gerresheimer shares you are expected to receive €42 in your first year as a dividend.
Dividend Amount
Here we look how much dividend is being paid, if any. Is it above what you can get in a savings account? It is up there with the best dividend paying companies?
  • Gerresheimer's pays a lower dividend yield than the bottom 25% of dividend payers in United Kingdom of Great Britain and Northern Ireland (2.69%).
  • Gerresheimer's dividend is below the markets top 25% of dividend payers in United Kingdom of Great Britain and Northern Ireland (7.48%).
Upcoming dividend payment

Purchase Gerresheimer before the 'Ex-dividend' to receive their next dividend payment.

Dividends are usually paid every 3 or 6 months, you can time your share purchase to take advantage of upcoming dividend payments.
Dividend payment calendar
Annualized Historical and Future Dividends
It is important to see if the dividend for a company is stable, and not wildly increasing/decreasing each year. This graph shows you the historical rate to count toward your assessment of the stock.

We also check to see if the dividend has increased in the past 10 years.
Raw Data
BATS-CHIXE:GXID Annualized Past and Future Dividends
Data Point Source Value
Past Annualized Dividend Yield S&P Global Market Data See Below
Past Dividends per Share Company Filings/ Annualized Dividend Payments See Below
Future Dividends per Share Estimates Average of up to 12 Analyst Estimates (S&P Global) See Below
Europe Life Sciences Industry Average Dividend Yield Market Cap Weighted Average of 12 Stocks 0.7%
United Kingdom of Great Britain and Northern Ireland Market Average Dividend Yield Market Cap Weighted Average of 629 Stocks 6%
United Kingdom of Great Britain and Northern Ireland Minimum Threshold Dividend Yield 10th Percentile 1.4%
United Kingdom of Great Britain and Northern Ireland Bottom 25% Dividend Yield 25th Percentile 2.7%
United Kingdom of Great Britain and Northern Ireland Top 25% Dividend Yield 75th Percentile 7.5%

Industry and Market average data is calculated daily.

Note all dividend per share amounts are annualized and not quarterly or other period.

BATS-CHIXE:GXID Future Dividends Estimate Data
Date (Data in €) Dividend per Share (annual) Avg. No. Analysts
2024-11-30 1.45 1.00
2023-11-30 1.30 2.00
2022-11-30 1.34 6.00
2021-11-30 1.24 11.00
2020-11-30 1.21 11.00
2020-03-31
BATS-CHIXE:GXID Past Annualized Dividends Data
Date (Data in €) Dividend per share (annual) Avg. Yield (%)
2020-02-19 1.200 1.951
2019-02-15 1.150 1.694
2018-02-22 1.100 1.668
2017-02-15 1.050 1.505
2016-02-11 0.850 1.205
2015-02-11 0.750 1.253
2014-02-14 0.700 1.445
2014-02-13 0.700 1.395
2013-02-14 0.650 1.412
2012-08-06 0.600 1.535
2011-02-10 0.500 1.506
2010-10-14 0.000 0.000
2010-10-06 0.000 0.000
2010-07-15 0.000 0.000
2010-07-14 0.000 0.000
2010-04-14 0.000 0.000
2010-02-09 0.000 0.000

Learn more about our ratios and growth rates in Simply Wall St’s analysis model >

  • Whilst dividend payments have been stable, Gerresheimer has been paying a dividend for less than 10 years.
  • Dividend payments have increased, but Gerresheimer only paid a dividend in the past 9 years.
Current Payout to shareholders
What portion of Gerresheimer's earnings are paid to the shareholders as a dividend.
  • Dividends paid are well covered by earnings (2.1x coverage).
Future Payout to shareholders
  • Dividends after 3 years are expected to be well covered by earnings (3.8x coverage).
X
Income/ dividend checks
We assess Gerresheimer's dividend by checking for:
  1. Firstly is the company paying a notable dividend (greater than 1.4%) - if not then the rest of the checks are ignored.
  2. Is current dividend yield above the bottom 25% of dividend payers? (1 check)
  3. Is current dividend yield above the top 25% of dividend payers? (1 check)
  4. Have they paid a dividend for 10 years, and during this period has the dividend been volatile (drop of more than 25%)? (1 check)
  5. If they have paid a dividend for 10 years has it increased in this time? (1 check)
  6. How sustainable is the dividend, can Gerresheimer afford to pay it from its earnings today and in 3 years (Payout ratio less than 90%)? (2 checks)
  7. Gerresheimer has a total score of 2/6, see the detailed checks below.


Full details on the Dividends part of the Simply Wall St company analysis model.

GXID Management

 What is the CEO of Gerresheimer's salary, the management and board of directors tenure and is there insider trading?

Management is one of the most important areas of a company. We look at unreasonable CEO compensation, how long the team and board of directors have been around for and insider trading.
CEO
Dietmar Siemssen
COMPENSATION €2,103,000
AGE 56
TENURE AS CEO 1.3 years
CEO Bio

Mr. Dietmar Siemssen serves as CEO & Member of Management Board at Gerresheimer AG since November 01, 2018. He served as the Chairman of Management Board, Chief Executive Officer and Managing Director of Stabilus GmbH. Mr. Siemssen served as Chairman of Management Board and Chief Executive Officer of Stabilus S.A. since 2014 until July 31, 2018. With 20 years of experience in the automotive industry, he joined Stabilus in 2011 and various management positions at Continental AG from 1994 to 2011, where he was responsible for Continental Automotive Corporation (CAC), a joint venture between Continental and Nisshinbo headquartered in Yokohama, Japan. He was Head of a joint venture between Continental and Nisshimbo in Yokohama, Japan, and as head of the Chassis and Safety division in Asia. He served as Member of Management Board at Stabilus S.A. since 2014 until August 1, 2018. He was also a Board Member of the Continental Chassis & Safety Division responsible for the Asia region. Starting 2009, Mr. Siemssen was also responsible for the overall business activities of Continental in Japan. He began his professional career in 1994 in various positions in Industrial Engineering and Logistics at ITT Automotive Europe-- which was acquired by Continental in the late 1990s. Mr. Siemssen's studies included a time at Technical University of Darmstadt, where he gained a diploma in industrial engineering specializing in mechanical engineering.

CEO Compensation
  • Dietmar's compensation has increased by more than 20% whilst company earnings have fallen more than 20% in the past year.
  • Dietmar's remuneration is about average for companies of similar size in United Kingdom of Great Britain and Northern Ireland.
Management Team Tenure

Average tenure and age of the Gerresheimer management team in years:

1.3
Average Tenure
44.5
Average Age
  • The average tenure for the Gerresheimer management team is less than 2 years, this suggests a new team.
Management Team

Dietmar Siemssen

TITLE
CEO & Member of Management Board
COMPENSATION
€2M
AGE
56
TENURE
1.3 yrs

Bernd Metzner

TITLE
CFO & Member of the Management Board
COMPENSATION
€991K
AGE
49
TENURE
0.8 yrs

Lukas Burkhardt

TITLE
Member of the Management Board
COMPENSATION
€1M
AGE
40
TENURE
2.2 yrs

Katja Schnitzler

TITLE
Group Director of Business Excellence & Continuous Improvement and Member of the Supervisory Board
COMPENSATION
€106K
AGE
38
TENURE
9.2 yrs

Jens-Philipp Briemle

TITLE
Head of Investor Relations
TENURE
0.3 yrs

Jens Kürten

TITLE
Group Senior Director of Communication & Marketing and Press Officer of Corporate Media

Helmut Schweiger

TITLE
MD & GM of Gerresheimer Horsovsky Tyn Plant
Board of Directors Tenure

Average tenure and age of the Gerresheimer board of directors in years:

7.8
Average Tenure
58.5
Average Age
  • The tenure for the Gerresheimer board of directors is about average.
Board of Directors

Axel Herberg

TITLE
Chairman of the Supervisory Board
COMPENSATION
€257K
AGE
61
TENURE
4.8 yrs

Francesco Grioli

TITLE
Deputy Chairman of the Supervisory Board
COMPENSATION
€167K
AGE
47
TENURE
8.3 yrs

Katja Schnitzler

TITLE
Group Director of Business Excellence & Continuous Improvement and Member of the Supervisory Board
COMPENSATION
€106K
AGE
38
TENURE
4.2 yrs

Theodor Stuth

TITLE
Member of the Supervisory Board
COMPENSATION
€126K
AGE
66
TENURE
11.8 yrs

Udo Vetter

TITLE
Member of the Supervisory Board
COMPENSATION
€104K
AGE
65
TENURE
12.8 yrs

Markus Rocholz

TITLE
Member of the Supervisory Board
COMPENSATION
€132K
AGE
49
TENURE
7.8 yrs

Karin Louise Dorrepaal

TITLE
Member of the Supervisory Board
COMPENSATION
€76K
AGE
58
TENURE
7.8 yrs

Peter Noé

TITLE
Member of the Supervisory Board
COMPENSATION
€78K
AGE
62
TENURE
8.2 yrs

Andrea Abt

TITLE
Member of the Supervisory Board
COMPENSATION
€104K
AGE
59
TENURE
4.8 yrs

Heike Arndt

TITLE
Member of the Supervisory Board
COMPENSATION
€78K
AGE
56
TENURE
2.8 yrs
Who owns this company?
Recent Insider Trading
  • No 3 month open market individual insider trading information.
Recent Insider Transactions
Announced Type Name Entity Role Start End Shares Max Price (€) Value (€)
X
Management checks
We assess Gerresheimer's management by checking for:
  1. Is the CEO's compensation unreasonable compared to market cap? (1 check)
  2. Has the CEO's compensation increased more than 20% whilst the EPS is down more then 20%? (1 check)
  3. Is the average tenure of the management team less than 2 years? (1 check)
  4. Is the average tenure of the board of directors team less than 3 years? (1 check)
  5. Gerresheimer has a total score of 0/6, this is not included on the snowflake, see the detailed checks below.


Note: We use the top 6 management executives and board members in our calculations.

Note 2: Insider trading include any internal stakeholders and these transactions .

Full details on the Management part of the Simply Wall St company analysis model.

GXID News

Simply Wall St News

GXID Company Info

Description

Gerresheimer AG manufactures and sells specialty glass and plastic products primarily for the pharma and healthcare industry worldwide. It operates through three divisions; Plastics & Devices, Primary Packaging Glass, and Advanced Technologies. The Plastics & Devices division offers drug delivery systems, including insulin pens, inhalers, pen systems, and injection systems; sterile and non-sterile prefillable syringe systems for the pharmaceutical and biotech industries; and disposables for various analysis systems that are used in laboratories and medical practices, quick tests for patients in medical practices or hospitals, skin-prick aids and lancets for diabetics, disposables and components for dialysis machines, and catheters and surgical devices. It also provides containers for the delivery of tablets and powders, liquid dosages, ophthalmic and rhinological applications, parenteral packaging applications, oral prescription medications, and cosmetics. The Primary Packaging Glass division offers glass primary packaging for medicines and cosmetics, such as pharma jars, ampoules, cartridges, injection vials, syrup and dropper bottles, tablet jars, and wide-neck jars, as well as injection, infusion, and transfusion bottles; flacons and pots for fragrances, deodorants, and care and decorative cosmetics; and bottles and jars for spirits and food. The Advanced Technologies division develops drug delivery products and platforms, such as micro pumps, which are used to self-administer medication for various therapeutic areas or Parkinson’s or heart failure for pharmaceutical and biotech customers. The company was founded in 1864 and is headquartered in Düsseldorf, Germany.

Details
Name: Gerresheimer AG
GXID
Exchange: BATS-CHIXE
Founded: 1864
€1,767,820,000
31,400,000
Website: http://www.gerresheimer.com
Address: Gerresheimer AG
Klaus-Bungert-Strasse 4,
Düsseldorf,
North Rhine-Westphalia, 40468,
Germany
Listings
Exchange Symbol Ticker Symbol Security Exchange Country Currency Listed on
XTRA GXI Common Stock XETRA Trading Platform DE EUR 11. Jun 2007
OTCPK GRRM.F Common Stock Pink Sheets LLC US USD 11. Jun 2007
DB GXI Common Stock Deutsche Boerse AG DE EUR 11. Jun 2007
LSE 0NTI Common Stock London Stock Exchange GB EUR 11. Jun 2007
SWX GXI Common Stock SIX Swiss Exchange CH CHF 11. Jun 2007
WBAG GXI Common Stock Wiener Boerse AG AT EUR 11. Jun 2007
ETLX GXI Common Stock Eurotlx IT EUR 11. Jun 2007
BATS-CHIXE GXID Common Stock BATS 'Chi-X Europe' GB EUR 11. Jun 2007
Number of employees
Current staff
Staff numbers
9,872
Gerresheimer employees.
Industry
Life Sciences Tools and Services
Pharmaceuticals & Biotech
Company Analysis and Financial Data Status
Area Date (UTC time)
Company Analysis updated: 2020/03/31 19:55
End of day share price update: 2020/03/30 00:00
Last estimates confirmation: 2020/03/26
Last earnings filing: 2020/02/19
Last earnings reported: 2019/11/30
Last annual earnings reported: 2019/11/30


All dates and times in UTC. All financial data provided by Standard & Poor’s Capital IQ.

Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.